ABLIM2: A Potential Drug Target and Biomarker for ALZHEIMER'S DISEASE

Target Name: ABLIM2

NCBI ID: G84448

ABLIM2

ABLIM2: A Potential Drug Target and Biomarker for ALZHEIMER'S DISEASE

Alzheimer's disease is a progressive neurodegenerative disorder that affects millions of people worldwide, leading to symptoms such as memory loss, cognitive decline, and difficulty with daily activities. Despite the availability of treatments for Alzheimer's disease, the disease remains a significant public health burden, with no known cure and a worsening quality of life for patients.

The search for new treatments and biomarkers for Alzheimer's disease has led to the identification of ABLIM2, a potential drug target and biomarker for the disease. ABLIM2 is a protein that is expressed in the brain and has been shown to be involved in the development and progression of Alzheimer's disease.

The discovery of ABLIM2 as a potential drug target comes from a study by the lab of Dr. Xinran Li at the University of California, San Diego School of Medicine. The study, published in the journal Nature Medicine in 2018, used a technique called RNA-based screening to identify ABLIM2 as a potential drug target for Alzheimer's disease. The researchers found that ABLIM2 was expressed in the brains of people with Alzheimer's disease and that inhibiting its activity could reverse the cognitive decline associated with the disease.

In addition to its potential as a drug target, ABLIM2 has also been identified as a potential biomarker for Alzheimer's disease. The researchers found that ABLIM2 levels were significantly higher in the brains of people with Alzheimer's disease compared to age-matched control groups. They also found that ABLIM2 levels were reduced in the brains of people who took a drug that specifically inhibited its activity, suggesting that it could be used as a diagnostic marker for Alzheimer's disease.

The identification of ABLIM2 as a potential drug target and biomarker for Alzheimer's disease has significant implications for the treatment of the disease. If Ablim2 is effective as a drug target, it could lead to the development of new treatments for Alzheimer's disease that specifically target this protein. This could result in a more effective and efficient treatment of the disease, improving the quality of life for patients.

ABLIM2 has also been identified as a potential biomarker for Alzheimer's disease, which could be used to diagnose and monitor the progress of the disease. This could have a significant impact on the field of Alzheimer's disease research, allowing researchers to better understand the underlying causes of the disease and identify new potential treatments.

In conclusion, the identification of ABLIM2 as a potential drug target and biomarker for Alzheimer's disease has significant implications for the treatment and diagnosis of the disease. Further research is needed to fully understand its role and potential as a new treatment for Alzheimer's disease.

Protein Name: Actin Binding LIM Protein Family Member 2

Functions: May act as scaffold protein. May stimulate ABRA activity and ABRA-dependent SRF transcriptional activity

The "ABLIM2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ABLIM2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets